FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362595512> ?p ?o ?g. }

• W4362595512 endingPage "2145" @default.
• W4362595512 startingPage "2145" @default.
• W4362595512 abstract "Abstract Background: Lurbinectedin monotherapy received accelerated FDA approval for adults with metastatic SCLC with disease progression on or after platinum-based chemotherapy. Lurbinectedin binds to GC-rich areas of gene promoters, blocks RNA-polymerase-II and induces degradation via ubiquitin/proteasome machinery. DNA binding of lurbinectedin results in double stranded DNA breaks and DNA damage that leads to cellular apoptosis. Schlafen 11 (SLFN11), a putative DNA/RNA helicase irreversibly binds to DNA replication forks resulting in replication block and is a predictive biomarker of response to therapeutics that elicit DNA damage including cisplatin, topoisomerase I/II inhibitors and PARP inhibitors. Objective: Evaluate the role of SLFN11 expression in predicting response to lurbinectedin, a DNA damaging agent, in human SCLC cell lines and in vivo models. Methods: Cytotoxicity assays: SCLC cell lines DMS 53, DMS 114, NCI-H69, NCI-H82, NCI-H196, NCI-H209, NCI-H211, NCI-H446, NCI-H526, NCI-H841, NCI-H889, NCI-H1048, and SHP-77 were tested with lurbinectedin dose range from 100 nM to 0.01 nM. Cell viability was determined by measuring intracellular ATP to determine percent cellular viability and IC50 of lurbinectedin. SLFN11 expression of 13 SCLC cell lines were retrieved as RNAseq values from the DepMap database. RNAseq value &gt;2 was assigned as SLFN11 high, values &lt;2 assigned as low. Western blot analysis was used to confirm protein expression. The difference in 10log IC50 between SLFN11 high and low lines is determined using Mann-Whitney test. In vivo efficacy studies: High SLFN11 (NCI-H1048) and low SLFN11 (NCI-H889 and NCI-H69) SCLC cell lines were used for xenograft studies in BALB/c nude mice. Mice were randomly allocated to 4 groups (n=8) as tumors reached a volume of 100 - 150 mm3. Groups received either vehicle or lurbinectedin at doses of 0.06, 0.12 or 0.18 mg/kg IV, QWx 3 weeks. Immunohistochemistry was used to assess SLFN11 protein expression on xenograft tissue. Results and Conclusions: Cell viability assays in 13 SCLC models confirm high SLFN11 expressing cell lines are 4-fold more sensitive to lurbinectedin compared to low SLFN11 expressing cell lines (ΔpIC50 = 0.64; p = 0.0451). The in vivo efficacy data confirms that the SLFN11 high NCI-H1048 model is more responsive with 90% TGI compared to 35% observed in SLFN11 low models (NCI-H889 and NCI-H69) at the highest lurbinectedin dose (p-value = 0.006). Efficacy data confirms correlation to SLFN11 protein expression, consistent with the RNA level association. Both in vitro cytotoxicity and in vivo efficacy studies in SCLC models confirm that high SLFN11 expression predicts response to lurbinectedin. Cell viability studies demonstrate that a limited set of SLFN11 low expressing cell lines are sensitive to lurbinectedin, suggesting a role for other genes. Proteomics and genomics work is underway to define additional response biomarkers Citation Format: Aparna Gupta, Kedar S. Vaidya, Janneke J.T.M. Melis, Robert Hauptschein, Graham Brock, Robin Humphreys. High SLFN11 expression correlates with sensitivity to lurbinectedin in small cell lung cancer (SCLC) models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2145." @default.
• W4362595512 created "2023-04-06" @default.
• W4362595512 creator A5002703541 @default.
• W4362595512 creator A5021045769 @default.
• W4362595512 creator A5063281948 @default.
• W4362595512 creator A5064121358 @default.
• W4362595512 creator A5071017875 @default.
• W4362595512 creator A5087955295 @default.
• W4362595512 date "2023-04-04" @default.
• W4362595512 modified "2023-09-30" @default.
• W4362595512 title "Abstract 2145: High SLFN11 expression correlates with sensitivity to lurbinectedin in small cell lung cancer (SCLC) models" @default.
• W4362595512 doi "https://doi.org/10.1158/1538-7445.am2023-2145" @default.
• W4362595512 hasPublicationYear "2023" @default.
• W4362595512 type Work @default.
• W4362595512 citedByCount "0" @default.
• W4362595512 crossrefType "journal-article" @default.
• W4362595512 hasAuthorship W4362595512A5002703541 @default.
• W4362595512 hasAuthorship W4362595512A5021045769 @default.
• W4362595512 hasAuthorship W4362595512A5063281948 @default.
• W4362595512 hasAuthorship W4362595512A5064121358 @default.
• W4362595512 hasAuthorship W4362595512A5071017875 @default.
• W4362595512 hasAuthorship W4362595512A5087955295 @default.
• W4362595512 hasConcept C143425029 @default.
• W4362595512 hasConcept C147897179 @default.
• W4362595512 hasConcept C153911025 @default.
• W4362595512 hasConcept C502942594 @default.
• W4362595512 hasConcept C53227056 @default.
• W4362595512 hasConcept C54355233 @default.
• W4362595512 hasConcept C552990157 @default.
• W4362595512 hasConcept C81885089 @default.
• W4362595512 hasConcept C86803240 @default.
• W4362595512 hasConceptScore W4362595512C143425029 @default.
• W4362595512 hasConceptScore W4362595512C147897179 @default.
• W4362595512 hasConceptScore W4362595512C153911025 @default.
• W4362595512 hasConceptScore W4362595512C502942594 @default.
• W4362595512 hasConceptScore W4362595512C53227056 @default.
• W4362595512 hasConceptScore W4362595512C54355233 @default.
• W4362595512 hasConceptScore W4362595512C552990157 @default.
• W4362595512 hasConceptScore W4362595512C81885089 @default.
• W4362595512 hasConceptScore W4362595512C86803240 @default.
• W4362595512 hasIssue "7_Supplement" @default.
• W4362595512 hasLocation W43625955121 @default.
• W4362595512 hasOpenAccess W4362595512 @default.
• W4362595512 hasPrimaryLocation W43625955121 @default.
• W4362595512 hasRelatedWork W1523914420 @default.
• W4362595512 hasRelatedWork W1992211004 @default.
• W4362595512 hasRelatedWork W2016254453 @default.
• W4362595512 hasRelatedWork W2052995223 @default.
• W4362595512 hasRelatedWork W2082928509 @default.
• W4362595512 hasRelatedWork W2088061849 @default.
• W4362595512 hasRelatedWork W2115330976 @default.
• W4362595512 hasRelatedWork W2168842837 @default.
• W4362595512 hasRelatedWork W2169830244 @default.
• W4362595512 hasRelatedWork W43480278 @default.
• W4362595512 hasVolume "83" @default.
• W4362595512 isParatext "false" @default.
• W4362595512 isRetracted "false" @default.
• W4362595512 workType "article" @default.